PARATEK PHARMACEUTICALS INC's ticker is and the CUSIP is 699374AB0. A total of 18 filers reported holding PARATEK PHARMACEUTICALS INC in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $354,000 | +2.6% | 400,000 | 0.0% | 0.09% | +17.8% |
| Q2 2022 | $345,000 | -2.5% | 400,000 | 0.0% | 0.07% | +19.7% |
| Q1 2022 | $354,000 | -3.3% | 400,000 | 0.0% | 0.06% | +17.3% |
| Q4 2021 | $366,000 | +3.7% | 400,000 | 0.0% | 0.05% | +2.0% |
| Q3 2021 | $353,000 | -1.1% | 400,000 | 0.0% | 0.05% | +6.2% |
| Q2 2021 | $357,000 | -0.3% | 400,000 | 0.0% | 0.05% | -5.9% |
| Q1 2021 | $358,000 | +3.2% | 400,000 | 0.0% | 0.05% | +4.1% |
| Q4 2020 | $347,000 | +5.5% | 400,000 | 0.0% | 0.05% | -14.0% |
| Q3 2020 | $329,000 | +1.9% | 400,000 | 0.0% | 0.06% | +9.6% |
| Q2 2020 | $323,000 | +22.8% | 400,000 | 0.0% | 0.05% | +20.9% |
| Q1 2020 | $263,000 | -8.0% | 400,000 | 0.0% | 0.04% | +48.3% |
| Q4 2019 | $286,000 | +2.1% | 400,000 | 0.0% | 0.03% | +3.6% |
| Q3 2019 | $280,000 | +2.6% | 400,000 | 0.0% | 0.03% | +7.7% |
| Q2 2019 | $273,000 | – | 400,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 37,825,000 | $25,876,000 | 3.78% |
| PenderFund Capital Management Ltd. | 13,060,000 | $9,300,000 | 3.13% |
| Telemetry Investments, L.L.C. | 1,500,000 | $1,084,000 | 3.13% |
| Context Capital Management, LLC | 1,600,000 | $1,157,000 | 0.66% |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 27,750,000 | $20,019,000,000 | 0.56% |
| PALISADE CAPITAL MANAGEMENT, LP | 3,750,000 | $2,712,000 | 0.08% |
| CAPSTONE INVESTMENT ADVISORS, LLC | 7,182,000 | $5,264,000 | 0.04% |
| AQR Arbitrage LLC | 3,050,000 | $2,236,000 | 0.03% |
| Teton Advisors, Inc. | 400,000 | $280,000 | 0.03% |
| GABELLI FUNDS LLC | 3,750,000 | $2,629,000 | 0.02% |